

Substitute for form 1445A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

COMPLETELY KNOWN

Application Number	10/544,261
Filing Date	August 3, 2005
First Named Inventor	Minoru Moriya et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	BY0006P
Sheet	1 of 4

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
/CC/		6569861		Bakthavatchalam et al.	05/27/2003
		6727264		Marzabadi et al.	04/27/2004
		6720324		Marzabadi et al.	04/13/2004
		6818772		Kym et al.	11/16/2004
		6930185		Ishihara et al.	08/16/2005
		6887889		Hobbe et al.	05/03/2005
		6472394		McKittrick et al.	10/29/2002
		6664273		Burnett et al.	12/16/2003
		6906075		DeSimone et al.	06/14/2005
		6900329		Clader et al.	05/31/2005
		2005/0049269		Wu et al.	03/03/2005
		2004/0106645		Blackburn et al.	06/03/2004
		2004/0063700		Cheng et al.	04/01/2004
		2003/0105094		Clader et al.	06/05/2003
		2003/0144261		Palani et al.	07/31/2003
		2003/0158177		Ishihara et al.	08/21/2003
		2002/0072604		Carpino et al.	06/13/2002
		2003/0212070		Schwink et al.	11/13/2003
		2003/0023085		Chen et al.	01/30/2003
/CC/		2004/0220404		Carpenier et al.	11/04/2004

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office Number	Kind Code (if known)		
/CC/		EP 1447402		Takeda Chemical Industries, Ltd.	08/18/2004
		EP 1219294		Takeda Chemical Industries, Ltd.	07/03/2002
		JP 2001 226269		Takeda Chemical Industries, Ltd.	08/21/2001
		JP 2002 003370A		Takeda Chemical Industries, Ltd.	01/09/2002
		JP 2002 371059		Takeda Chemical Industries, Ltd.	12/26/2002
		WO 02/088089		Banyu Pharmaceutical Co., Ltd.	11/07/2002
		WO 01/21577		Takeda Chemical Industries, Ltd.	03/29/2001
		WO 01/82925		Takeda Chemical Industries, Ltd.	08/11/2001
		WO 02/06245		Synaptic Pharmaceutical Corporation	01/24/2002
/CC/		WO 02/02744		Synaptic Pharmaceutical Corporation	01/10/2002

Examiner Signature	/Celia Chang/	Date Considered	10/15/2008
--------------------	---------------	-----------------	------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 7/13/2005

(use as many sheets as necessary)

COMPLETELY KNOWN

Application Number	10544,261
Filing Date	August 3, 2005
First Named Inventor	Minoru Moriya et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	BY0006P

Sheet 2 of 4

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patente or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
/CC/			WO 01/21169		keda Chemical Industries, Ltd.	03/29/2001
			WO 04/004714		Synaptic Pharmaceutical Corporation	01/15/2004
			WO 04/043958		Tularik Inc.	05/27/2004
			WO 04/028459		Tularik Inc.	04/08/2004
			WO 03/045313		Merck & Co., Inc.	06/05/2003
			WO 02/00654		Pfizer Products Inc.	01/03/2002
			WO 02/076929		Pharmacopeia, Inc.	10/03/2002
			WO 03/087046		7TM Pharma A/S	10/23/2003
			WO 03/087044		7TM Pharma A/S	10/23/2003
/CC/			WO 03/070244		Abbott Laboratories	08/28/2003

Examiner
Signature

/Celia Chang/

Date Considered

10/15/2008

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc.. -7/12/2005

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Application Number	10/544,261
Filing Date	August 3, 2005
First Named Inventor	Minoru Moriya et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	BY0006P

Sheet 3 of 4

[illegible]

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number Kind Code (if known)		
/CC/			WO 03/087045	7TM Pharma A/S	10/23/2003
			WO 03/028641	Taisho Pharmaceutical Co., Ltd.	04/10/2003
			WO 03/097047	Eli Lilly and Company	11/27/2003
			WO 03/045920	Merck & Co., Inc.	06/05/2003
/CC/			JP 11-507344	Canon Inc.	01/14/1993

Examiner Signature	/Celia Chang/	Date Considered	10/15/2008
-----------------------	---------------	--------------------	------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder) Merck & Co., Inc., 7/12/2005

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

COMPLETELY KNOWN

Application Number	10/544,261
Filing Date	August 3, 2005
First Named Inventor	Minoru Moriya et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	BY0006P

Sheet	4	of	4
-------	---	----	---

Examiner
Initials*Cite
No.

Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.

/CC/

AA

Roufos et al., J. Med. Chem., (1996), Vol. 39(7), pp. 1514-20, "A structure -- Activity relationship study of novel phenylacetamides which are sodium channel blockers"

AB

Dyke et al., *Exp. Opin. Ther. Patents* (2005), Vol. 15, pp. 1303-1313, "Recent developments in the discovery of MCH-1R antagonists for the treatment of obesity -- an update"

--	--

Kowalski et al., *Exp. Opin. Ther. Patents* (2004), Vol. 13, pp. 1113-1122, "Therapeutic potential of melanin-concentrating hormone-1 receptor antagonists for the treatment of obesity"

AD

Clark et al., *J. Med. Chem.*, (2004), Vol. 47, pp. 3962-3971, "A virtual screening approach to finding novel and potent antagonists at the melanin-concentrating hormone 1 receptor"

/CC/

AE

Arienzo et al., *Bioorg. & Medicinal Chem. Letters*, (2004), Vol. 14, pp. 4099-4102, "Structure-activity relationships of a novel series of melanin-concentrating hormone (MCH) receptor antagonists"

Examiner
Signature

/Celia Chang/

Date
Considered

10/15/2008

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IOS Form" (IOS Folder), Merck & Co., Inc., -7/12/2005